Rhythm Pharmaceuticals, Inc. (RYTM)
117.62
+12.85
(+12.26%)
USD |
NASDAQ |
Dec 11, 16:00
117.67
+0.05
(+0.04%)
After-Hours: 05:18
Rhythm Pharmaceuticals Cash from Investing (Quarterly): -246.35M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -427.00M |
| Terns Pharmaceuticals, Inc. | 24.50M |
| Altimmune, Inc. | -149.32M |
| Viking Therapeutics, Inc. | 160.02M |
| Cidara Therapeutics, Inc. | -176.47M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -26.62M |
| Cash from Financing (Quarterly) | 189.30M |
| Free Cash Flow | -149.13M |
| Free Cash Flow Per Share (Quarterly) | -1.005 |
| Free Cash Flow to Equity (Quarterly) | -67.12M |
| Free Cash Flow to Firm (Quarterly) | -61.87M |
| Free Cash Flow Yield | -1.99% |